195 related articles for article (PubMed ID: 9305475)
1. Retrograde colonic spread of a new mesalazine rectal enema in patients with distal ulcerative colitis.
Gionchetti P; Venturi A; Rizzello F; Corbelli C; Fanti S; Ferretti M; Boschi S; Miglioli M; Campieri M
Aliment Pharmacol Ther; 1997 Aug; 11(4):679-84. PubMed ID: 9305475
[TBL] [Abstract][Full Text] [Related]
2. Distribution of mesalazine enemas in active and quiescent ulcerative colitis.
van Bodegraven AA; Boer RO; Lourens J; Tuynman HA; Sindram JW
Aliment Pharmacol Ther; 1996 Jun; 10(3):327-32. PubMed ID: 8791959
[TBL] [Abstract][Full Text] [Related]
3. Colonic spread of three rectally administered mesalazine (Pentasa) dosage forms in healthy volunteers as assessed by gamma scintigraphy.
Brown J; Haines S; Wilding IR
Aliment Pharmacol Ther; 1997 Aug; 11(4):685-91. PubMed ID: 9305476
[TBL] [Abstract][Full Text] [Related]
4. Colonic spreading of a non-chlorofluorocarbon mesalazine rectal foam enema in patients with quiescent ulcerative colitis.
Wilding IR; Kenyon CJ; Chauhan S; Hooper G; Marshall S; McCracken JS; Staab HJ; Armbrecht J
Aliment Pharmacol Ther; 1995 Apr; 9(2):161-6. PubMed ID: 7605856
[TBL] [Abstract][Full Text] [Related]
5. Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis.
Campieri M; Corbelli C; Gionchetti P; Brignola C; Belluzzi A; Di Febo G; Zagni P; Brunetti G; Miglioli M; Barbara L
Dig Dis Sci; 1992 Dec; 37(12):1890-7. PubMed ID: 1473437
[TBL] [Abstract][Full Text] [Related]
6. Distribution of mesalamine enemas in patients with active distal ulcerative colitis.
Chapman NJ; Brown ML; Phillips SF; Tremaine WJ; Schroeder KW; Dewanjee MK; Zinsmeister AR
Mayo Clin Proc; 1992 Mar; 67(3):245-8. PubMed ID: 1545592
[TBL] [Abstract][Full Text] [Related]
7. Scintigraphic imaging and absorption of a 5-aminosalicylic acid enema in patients with ileorectal anastomosis.
Lisciandrano D; Benti R; Ranzi T; Baldassarri AR; Bruno A; Bianchi PA; Gerundini P
J Nucl Med; 1999 Oct; 40(10):1630-6. PubMed ID: 10520702
[TBL] [Abstract][Full Text] [Related]
8. Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment.
Frieri G; Pimpo MT; Palumbo GC; Onori L; Viscido A; Latella G; Galletti B; Pantaleoni GC; Caprilli R
Aliment Pharmacol Ther; 1999 Nov; 13(11):1413-7. PubMed ID: 10571596
[TBL] [Abstract][Full Text] [Related]
9. Retrograde spread of mesalazine (5-aminosalicylic acid)-containing enema in patients with ulcerative colitis.
Tiel-van Buul MM; Mulder CJ; van Royen EA; Wiltink EH; Tytgat GN
Clin Pharmacokinet; 1991 Mar; 20(3):247-51. PubMed ID: 2025983
[TBL] [Abstract][Full Text] [Related]
10. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
Ardizzone S; Doldo P; Ranzi T; Sturniolo GC; Giglio LA; Annese V; D'Arienzo A; Gaia E; Gullini S; Riegler G; Valentini M; Massa P; Del Piano M; Rossini F; Guidetti CS; Pera A; Greinwald R; Bianchi Porro G
Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):677-84. PubMed ID: 10730559
[TBL] [Abstract][Full Text] [Related]
11. A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial.
Gionchetti P; Ardizzone S; Benvenuti ME; Bianchi Porro G; Biasco G; Cesari P; D'albasio G; De Franchis R; Monteleone G; Pallone F; Ranzi T; Trallori G; Valpiani D; Vecchi M; Campieri M
Aliment Pharmacol Ther; 1999 Mar; 13(3):381-8. PubMed ID: 10102972
[TBL] [Abstract][Full Text] [Related]
12. Simulated comparison of topical and oral formulations of 5-aminosalicylate for the treatment of ulcerative colitis.
Stobaugh DJ; Deepak P; Thorpe M; Hannon B; Ehrenpreis ED
Inflamm Bowel Dis; 2013 Feb; 19(2):301-8. PubMed ID: 22644716
[TBL] [Abstract][Full Text] [Related]
13. A clinical trial on absorption and N-acetylation of oral and rectal mesalazine.
Dilger K; Trenk D; Rössle M; Cap M; Zähringer A; Wacheck V; Remmler C; Cascorbi I; Kreisel W; Novacek G
Eur J Clin Invest; 2007 Jul; 37(7):558-65. PubMed ID: 17576207
[TBL] [Abstract][Full Text] [Related]
14. Quantitative distribution of radiolabeled 5-aminosalicylic acid enemas in patients with left-sided ulcerative colitis.
Vitti RA; Meyers F; Knight LC; Siegel JA; Malmud LS; Fisher RS
Dig Dis Sci; 1989 Nov; 34(11):1792-7. PubMed ID: 2582990
[TBL] [Abstract][Full Text] [Related]
15. Retrograde distribution of a new 5-aminosalicylic acid enema in patients with ulcerative colitis.
Almer S; Ekberg S; Ström M
Gastroenterol Clin Biol; 1992; 16(6-7):564-8. PubMed ID: 1526419
[TBL] [Abstract][Full Text] [Related]
16. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study.
Pokrotnieks J; Marlicz K; Paradowski L; Margus B; Zaborowski P; Greinwald R
Aliment Pharmacol Ther; 2000 Sep; 14(9):1191-8. PubMed ID: 10971236
[TBL] [Abstract][Full Text] [Related]
18. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine.
Støa-Birketvedt G; Florholmen J
Aliment Pharmacol Ther; 1999 Mar; 13(3):357-61. PubMed ID: 10102969
[TBL] [Abstract][Full Text] [Related]
19. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life.
Probert CS; Dignass AU; Lindgren S; Oudkerk Pool M; Marteau P
J Crohns Colitis; 2014 Mar; 8(3):200-7. PubMed ID: 24012063
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pilot efficacy of a mesalazine rectal gel in distal ulcerative colitis.
Aumais G; Lefebvre M; Massicotte J; Tremblay C; Kasbo J; Brunet JS; Cardinal C; Grace M; Spénard J
Drugs R D; 2005; 6(1):41-6. PubMed ID: 15801866
[No Abstract] [Full Text] [Related]
[Next] [New Search]
